HEMATOLOGICAL MALIGNANCIES

This study tests a new drug called teclistamab in about 194 people with multiple myeloma, a type of blood cancer, that has returned or not responded to prior treatments. The drug is designed to help the immune system attack cancer cells. The main goal is to see how many patients …

This early-stage study tests a new drug called talquetamab in people with multiple myeloma that has come back or stopped responding to other treatments. The drug is designed to help the immune system attack cancer cells. The main goals are to check safety and find the best dose f…

This study tests two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs shri…

This early-stage study tests a new drug, teclistamab, in about 300 people with multiple myeloma that has come back or not responded to other treatments. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side e…

This study tests a new drug called AZD9829 in people with blood cancers that have a specific marker (CD123) and have not responded to other treatments. The main goals are to find a safe dose and check for side effects. About 56 adults will take part, receiving the drug alone or w…

This study looked at whether relaxation breathing exercises can help manage nausea and vomiting caused by chemotherapy in people with blood cancers. Sixty-eight patients took part, with half doing breathing exercises three times a day plus standard care, and the other half receiv…

This study looks at whether weighted blankets can improve sleep quality in people with blood cancers. Twenty adult outpatients at MD Anderson Cancer Center will try the blankets, and researchers will track any side effects and changes in sleep. The goal is to see if this simple, …

This study was designed to track immune system recovery and test a pneumococcal vaccine (PCV-21) in people receiving CAR-T therapy for blood cancers or solid tumors. Participants would have had regular clinic visits and blood tests for up to 24 months. However, the study was with…